Literature DB >> 30626603

Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers.

Carminia Maria Della Corte1, Lauren Averett Byers2.   

Abstract

Mutations in STK11 (LKB1) are a major cause of primary resistance to immunotherapy in non-small cell lung cancer. Kitajima and colleagues dissect the underlying mechanism of this immune-resistant phenotype, demonstrating that LKB1 loss leads directly to suppression of stimulator of interferon genes (STING) and insensitivity to cytoplasmic double-strand DNA detection. Therapies that reactivate LKB1 or theSTING pathway may boost anticancer immune response in cancers with resistance to immune-checkpoint blockade.See related article by Kitajima et al., p. 34. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30626603      PMCID： PMC8330553          DOI： 10.1158/2159-8290.CD-18-1286

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  7 in total

1.  Design of amidobenzimidazole STING receptor agonists with systemic activity.

Authors:  Joshi M Ramanjulu; G Scott Pesiridis; Jingsong Yang; Nestor Concha; Robert Singhaus; Shu-Yun Zhang; Jean-Luc Tran; Patrick Moore; Stephanie Lehmann; H Christian Eberl; Marcel Muelbaier; Jessica L Schneck; Jim Clemens; Michael Adam; John Mehlmann; Joseph Romano; Angel Morales; James Kang; Lara Leister; Todd L Graybill; Adam K Charnley; Guosen Ye; Neysa Nevins; Kamelia Behnia; Amaya I Wolf; Viera Kasparcova; Kelvin Nurse; Liping Wang; Ana C Puhl; Yue Li; Michael Klein; Christopher B Hopson; Jeffrey Guss; Marcus Bantscheff; Giovanna Bergamini; Michael A Reilly; Yiqian Lian; Kevin J Duffy; Jerry Adams; Kevin P Foley; Peter J Gough; Robert W Marquis; James Smothers; Axel Hoos; John Bertin
Journal:  Nature       Date:  2018-11-07       Impact factor: 49.962

2.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Authors:  Ferdinandos Skoulidis; Lauren A Byers; Lixia Diao; Vassiliki A Papadimitrakopoulou; Pan Tong; Julie Izzo; Carmen Behrens; Humam Kadara; Edwin R Parra; Jaime Rodriguez Canales; Jianjun Zhang; Uma Giri; Jayanthi Gudikote; Maria A Cortez; Chao Yang; Youhong Fan; Michael Peyton; Luc Girard; Kevin R Coombes; Carlo Toniatti; Timothy P Heffernan; Murim Choi; Garrett M Frampton; Vincent Miller; John N Weinstein; Roy S Herbst; Kwok-Kin Wong; Jianhua Zhang; Padmanee Sharma; Gordon B Mills; Waun K Hong; John D Minna; James P Allison; Andrew Futreal; Jing Wang; Ignacio I Wistuba; John V Heymach
Journal:  Cancer Discov       Date:  2015-06-11       Impact factor: 39.397

Review 3.  Targeting DNA damage repair in small cell lung cancer and the biomarker landscape.

Authors:  Triparna Sen; Carl M Gay; Lauren Averett Byers
Journal:  Transl Lung Cancer Res       Date:  2018-02

4.  The LKB1-AMPK pathway: metabolism and growth control in tumour suppression.

Authors:  David B Shackelford; Reuben J Shaw
Journal:  Nat Rev Cancer       Date:  2009-08       Impact factor: 60.716

5.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Authors:  Ferdinandos Skoulidis; Michael E Goldberg; Danielle M Greenawalt; Matthew D Hellmann; Mark M Awad; Justin F Gainor; Alexa B Schrock; Ryan J Hartmaier; Sally E Trabucco; Laurie Gay; Siraj M Ali; Julia A Elvin; Gaurav Singal; Jeffrey S Ross; David Fabrizio; Peter M Szabo; Han Chang; Ariella Sasson; Sujaya Srinivasan; Stefan Kirov; Joseph Szustakowski; Patrik Vitazka; Robin Edwards; Jose A Bufill; Neelesh Sharma; Sai-Hong I Ou; Nir Peled; David R Spigel; Hira Rizvi; Elizabeth Jimenez Aguilar; Brett W Carter; Jeremy Erasmus; Darragh F Halpenny; Andrew J Plodkowski; Niamh M Long; Mizuki Nishino; Warren L Denning; Ana Galan-Cobo; Haifa Hamdi; Taghreed Hirz; Pan Tong; Jing Wang; Jaime Rodriguez-Canales; Pamela A Villalobos; Edwin R Parra; Neda Kalhor; Lynette M Sholl; Jennifer L Sauter; Achim A Jungbluth; Mari Mino-Kenudson; Roxana Azimi; Yasir Y Elamin; Jianjun Zhang; Giulia C Leonardi; Fei Jiang; Kwok-Kin Wong; J Jack Lee; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Vincent A Miller; Garrett M Frampton; Jedd D Wolchok; Alice T Shaw; Pasi A Jänne; Philip J Stephens; Charles M Rudin; William J Geese; Lee A Albacker; John V Heymach
Journal:  Cancer Discov       Date:  2018-05-17       Impact factor: 39.397

6.  Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer.

Authors:  Shunsuke Kitajima; Elena Ivanova; Sujuan Guo; Ryohei Yoshida; Marco Campisi; Shriram K Sundararaman; Shoichiro Tange; Yoichiro Mitsuishi; Tran C Thai; Sayuri Masuda; Brandon P Piel; Lynette M Sholl; Paul T Kirschmeier; Cloud P Paweletz; Hideo Watanabe; Mamiko Yajima; David A Barbie
Journal:  Cancer Discov       Date:  2018-10-08       Impact factor: 39.397

7.  STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.

Authors:  Shohei Koyama; Esra A Akbay; Yvonne Y Li; Amir R Aref; Ferdinandos Skoulidis; Grit S Herter-Sprie; Kevin A Buczkowski; Yan Liu; Mark M Awad; Warren L Denning; Lixia Diao; Jing Wang; Edwin R Parra-Cuentas; Ignacio I Wistuba; Margaret Soucheray; Tran Thai; Hajime Asahina; Shunsuke Kitajima; Abigail Altabef; Jillian D Cavanaugh; Kevin Rhee; Peng Gao; Haikuo Zhang; Peter E Fecci; Takeshi Shimamura; Matthew D Hellmann; John V Heymach; F Stephen Hodi; Gordon J Freeman; David A Barbie; Glenn Dranoff; Peter S Hammerman; Kwok-Kin Wong
Journal:  Cancer Res       Date:  2016-02-01       Impact factor: 12.701
  7 in total
  11 in total

1.  Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.

Authors:  Zoltan Lohinai; Balazs Dome; David Dora; Christopher Rivard; Hui Yu; Shivaun Lueke Pickard; Viktoria Laszlo; Tunde Harko; Zsolt Megyesfalvi; Csongor Gerdan; Elek Dinya; Konrad Hoetzenecker; Fred R Hirsch
Journal:  Cancer Immunol Immunother       Date:  2022-08-17       Impact factor: 6.630

2.  STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.

Authors:  Carminia M Della Corte; Triparna Sen; Carl M Gay; Kavya Ramkumar; Lixia Diao; Robert J Cardnell; Bertha Leticia Rodriguez; C Allison Stewart; Vassiliki A Papadimitrakopoulou; Laura Gibson; Jared J Fradette; Qi Wang; Youhong Fan; David H Peng; Marcelo V Negrao; Ignacio I Wistuba; Junya Fujimoto; Luisa M Solis Soto; Carmen Behrens; Ferdinandos Skoulidis; John V Heymach; Jing Wang; Don L Gibbons; Lauren A Byers
Journal:  J Thorac Oncol       Date:  2020-02-15       Impact factor: 15.609

Review 3.  Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy.

Authors:  Giulia Mazzaschi; Alessandro Leonetti; Roberta Minari; Letizia Gnetti; Federico Quaini; Marcello Tiseo; Francesco Facchinetti
Journal:  Curr Treat Options Oncol       Date:  2021-09-15

Review 4.  The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas.

Authors:  Baharia Mograbi; Simon Heeke; Paul Hofman
Journal:  Diagnostics (Basel)       Date:  2021-01-29

Review 5.  Unraveling the Role of STK11/LKB1 in Non-small Cell Lung Cancer.

Authors:  Vikram Sumbly; Ian Landry
Journal:  Cureus       Date:  2022-01-10

6.  Metformin Combining PD-1 Inhibitor Enhanced Anti-Tumor Efficacy in STK11 Mutant Lung Cancer Through AXIN-1-Dependent Inhibition of STING Ubiquitination.

Authors:  Zhiguo Wang; Conghua Lu; Kejun Zhang; Caiyu Lin; Fang Wu; Xiaolin Tang; Di Wu; Yuanyao Dou; Rui Han; Yubo Wang; Chao Hou; Qin Ouyang; Mingxia Feng; Yong He; Li Li
Journal:  Front Mol Biosci       Date:  2022-02-23

7.  Loss of STING expression is prognostic in non-small cell lung cancer.

Authors:  Zoltan Lohinai; David Dora; Charles Caldwell; Christopher J Rivard; Kenichi Suda; Hui Yu; Gareth Rivalland; Kim Ellison; Leslie Rozeboom; Rafal Dziadziuszko; Paul Mitchell; Thomas John; Inigo S Millan; Shengxiang Ren; Fred R Hirsch
Journal:  J Surg Oncol       Date:  2022-01-31       Impact factor: 2.885

8.  Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?

Authors:  Carminia Maria Della Corte; Flora Cimmino; Floriana Morgillo
Journal:  Explor Target Antitumor Ther       Date:  2021-04-30

9.  Long non-coding RNA MALAT1 targeting STING transcription promotes bronchopulmonary dysplasia through regulation of CREB.

Authors:  Jia-He Chen; Dan-Dan Feng; Yu-Fei Chen; Cai-Xia Yang; Chen-Xia Juan; Qian Cao; Xi Chen; Shuang Liu; Guo-Ping Zhou
Journal:  J Cell Mol Med       Date:  2020-08-18       Impact factor: 5.310

10.  Tumor-Derived cGAMP Regulates Activation of the Vasculature.

Authors:  Marco Campisi; Shriram K Sundararaman; Sarah E Shelton; Erik H Knelson; Navin R Mahadevan; Ryohei Yoshida; Tetsuo Tani; Elena Ivanova; Israel Cañadas; Tatsuya Osaki; Sharon Wei Ling Lee; Tran Thai; Saemi Han; Brandon P Piel; Sean Gilhooley; Cloud P Paweletz; Valeria Chiono; Roger D Kamm; Shunsuke Kitajima; David A Barbie
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.